Stuti Dalal¹, Achintya Benegal¹, Suman Chaudhary² and Ajay Ashok²*

¹School of Medicine, University of Missouri, Kansas City, MO, USA
²Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA

*Corresponding Author: Ajay Ashok, Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.

Received: July 20, 2023; Published: August 31, 2023

Abstract

Glaucoma is a leading cause of blindness, and it is defined as a neurodegenerative disorder that ultimately effects the retinal layers resulting in blindness. Several therapeutics aim at minimizing intraocular pressure, a major hallmark of glaucoma. A comprehensive understanding of existing therapeutics and their drawbacks will help us design blueprints for effective therapeutics and management regimes for effective glaucoma management. The current review will present an insight into current and developing therapeutics existing for efficient glaucoma management.

 Keywords: Glaucoma; Drugs; Clinical Studies

References

1. Stein JD., et al. “Glaucoma in adults-Screening, diagnosis, and management: A review”. The Journal of the American Medical Association2 (2021): 164-174.
2. Talaat K., et al. “Types of Glaucoma and Associated Comorbidities Among Patients at King Abdulaziz Medical City, Jeddah”. Cureus6 (2021).
3. Weinreb RN., et al. “The pathophysiology and treatment of glaucoma: a review”. The Journal of the American Medical Association18 (2014): 1901-1911.
4. Ashok A., et al. “Retinal Degeneration and Alzheimer's Disease: An Evolving Link”. International Journal of Molecular Sciences19 (2020).
5. Zhang N., et al. “Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review”. Scientific Reports1 (2021): 1-12.
6. Dietze J., et al. Glaucoma (2022).
7. Wiggs JL and LR Pasquale. “Genetics of glaucoma”. Human Molecular GeneticsR1 (2017): R21-R27.
8. Ashok A., et al. “Prion protein modulates endothelial to mesenchyme-like transition in trabecular meshwork cells: Implications for primary open angle glaucoma”. Scientific Reports1 (2019): 13090.
9. Ashok A., et al. “TGFβ2-hepcidin feed-forward loop in the trabecular meshwork implicates iron in glaucomatous pathology”. Investigative Ophthalmology and Visual Science3 (2020): 24-24.
10. Adulla A., et al. “α-Synuclein modulates fibronectin expression in the trabecular meshwork independent of TGFβ2”. Experimental Eye Research 226 (2023): 109351.
11. Ashok A., et al. “Epigenetic Regulation of Optic Nerve Development, Protection, and Repair”. International Journal of Molecular Sciences16 (2022).
12. Jacobs DS., et al. “Open-angle glaucoma: epidemiology, clinical presentation, and diagnosis”. In: UpToDate, UpToDate, Waltham, MA, USA (2016).
13. Dikopf MS., et al. “Topical treatment of glaucoma: established and emerging pharmacology”. Expert Opinion on Pharmacotherapy9 (2017): 885-898.
14. Costagliola C., et al. “Pharmacotherapy of intraocular pressure–part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides”. Expert Opinion on Pharmacotherapy17 (2009): 2859-2870.
15. Cvenkel B and M Kolko. “Current medical therapy and future trends in the management of glaucoma treatment”. Journal of Ophthalmology (2020).
16. Schuster AK., et al. “The diagnosis and treatment of glaucoma”. Deutsches Ärzteblatt International13 (2020): 225.
17. Alm A., et al. “Side effects associated with prostaglandin analog therapy”. Survey of Ophthalmology6 (2008): S93-S105.
18. Realini T. “A history of glaucoma pharmacology”. Optometry and Vision Science1 (2011): 36-38.
19. Garway-Heath DF., et al. “Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial”. The Lancet9975 (2015): 1295-1304.
20. Rao S and Narayanan. “A randomised open label comparative clinical trial on the efficacy of latanoprost and timolol in primary open angle glaucoma”. Journal of Clinical and Diagnostic Research: JCDR1 (2016): FC13.
21. Winkler NS and M Fautsch. “Effects of prostaglandin analogues on aqueous humor outflow pathways”. Journal of Ocular Pharmacology and Therapeutics2-3 (2014): 102-109.
22. Simmons ST., et al. “Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials”. Advances in Therapy4 (2004): 247-262.
23. Curran MP. “Bimatoprost”. Drugs and Aging12 (2009): 1049-1071.
24. Brooks A and W Gillies. “Ocular β-blockers in Glaucoma management”. Drugs and Aging3 (1992): 208-221.
25. Li T., et al. “Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis”. Ophthalmology1 (2016): 129-140.
26. Skov AG., et al. “Comparative efficacy and safety of preserved versus preservative‐free beta‐blockers in patients with glaucoma or ocular hypertension: a systematic review”. Acta Ophthalmologica3 (2022): 253-261.
27. Viswanathan A., et al. “Resource utilization among glaucoma patients in the UK treated with beta-blocker and Non-Beta-Blocker adjunctive therapy: a retrospective cohort analysis”. Advances in Therapy7 (2017): 1695-1706.
28. Silverstone B and T Marcus. “Hypoglycemia due to ophthalmic timolol in a diabetic”. Harefuah12 (1990): 693-694.
29. Roughead EE., et al. “Managing glaucoma in those with co-morbidity: not as easy as it seems”. Ophthalmic Epidemiology2 (2012): 74-82.
30. Arthur S and LB Cantor. “Update on the role of alpha-agonists in glaucoma management”. Experimental Eye Research3 (2011): 271-283.
31. Wen R., et al. “α2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage”. Journal of Neuroscience19 (1996): 5986-5992.
32. Burke J and M Schwartz. “Preclinical evaluation of brimonidine”. Survey of Ophthalmology 41 (1996): S9-S18.
33. Hoyng PF and LM Van Beek. “Pharmacological therapy for glaucoma”. Drugs3 (2000): 411-434.
34. Aslam S and V Gupta. “Carbonic anhydrase inhibitors”. Stat Pearls (2022).
35. Kumar S., et al. “Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors”. European Journal of Medicinal Chemistry 209 (2021): 112923.
36. Balfour JA and MI Wilde. “Dorzolamide”. Drugs and Aging5 (1997): 384-403.
37. Iester M. “Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension”. Clinical Ophthalmology3 (2008): 517.
38. Mohan N., et al. “Newer advances in medical management of glaucoma”. Indian Journal of Ophthalmology6 (2022): 1920-1930.
39. Sturdivant JM., et al. “Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma”. Bioorganic and Medicinal Chemistry Letters10 (2016): 2475-2480.
40. Villegas NC and WS Lee. “Effectiveness of netarsudil as an additional therapy for glaucoma in patients already on maximally tolerated medical therapy”. Clinical Ophthalmology 15 (2021): 4367.
41. Al-Humimat G., et al. “Investigational Rho kinase inhibitors for the treatment of glaucoma”. Journal of Experimental Pharmacology 13 (2021): 197.
42. Khouri AS., et al. “Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study”. American Journal of Ophthalmology 204 (2019): 97-104.
43. Kahook MY., et al. “Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: rho kinase elevated IOP treatment trial (ROCKET-2)”. American Journal of Ophthalmology 200 (2019): 130-137.
44. Serle JB., et al. “Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)”. American Journal of Ophthalmology 186 (2018): 116-127.
45. Tribble JR., et al. “Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction”. Redox Biology 43 (2021): 101988.
46. De Moraes CG., et al. “Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial”. JAMA Ophthalmology1 (2022): 11-18.
47. Anton A., et al. “The Effect of Oral Citicoline and Docosahexaenoic Acid on the Visual Field of Patients with Glaucoma: A Randomized Trial”. Life10 (2022).
48. Rossetti L., et al. “Can Treatment with Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial”. Journal of Glaucoma7 (2020): 513-520.
49. Williams PA., et al. “Nicotinamide treatment robustly protects from inherited mouse glaucoma”. Communicative and Integrative Biology1 (2018): e1356956.
50. Williams PA., et al. “Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice”. Science6326 (2017): 756-760.

Citation

Citation: Ajay Ashok., et al. “Recent Pharmacological Advancement in Glaucoma Management".Acta Scientific Ophthalmology 6.9 (2023): 60-65.

Copyright

Copyright: © 2023 Ajay Ashok., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.